Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Haematologica - 1 Apr 2018

Bhatia Ankush, Ulaner Gary, Rampal Raajit, Hyman David M, Abdel-Wahab Omar, Durham Benjamin H, Dogan Ahmet, Ozkaya Neval, Lacouture Mario E, Hajdenberg Julio, Ganzel Chezi, Diamond Eli L

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Child
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 29472347
DOI: 10.3324/haematol.2017.185298
PMCID: PMC5865413

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.PMID 29472347Read ↗

Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.Semantic proximity Read ↗

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.Semantic proximity Read ↗

Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm.Semantic proximity Read ↗

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.Semantic proximity Read ↗

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Semantic proximity Read ↗

Dabrafenib Active in Rare NSCLC Subtype.Semantic proximity Read ↗

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.Semantic proximity Read ↗

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Semantic proximity Read ↗

Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.